QSAM Biosciences (QSAM) 10-Q 13 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 13, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-41337
Entity Registrant Name	QSAM Biosciences, Inc.
Entity Central Index Key	0001310527
Entity Tax Identification Number	20-1602779
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	9442 Capital of Texas Hwy N
Entity Address, Address Line Two	Plaza 1
Entity Address, Address Line Three	Suite 500
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78759
City Area Code	(512)
Local Phone Number	343-4558
Title of 12(g) Security	Common Stock, par value $0.0001
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		3,470,811

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash	$ 446,593	$ 225,276
Prepaid expenses and other current assets	63,724	139,345
Subscription receivable	100,000
TOTAL CURRENT ASSETS	610,317	364,621
TOTAL ASSETS	610,317	364,621
CURRENT LIABILITIES
Accounts payable and accrued expenses	1,206,269	745,011
Accrued payroll and related expenses	79,166	79,166
Accrued Series B preferred stock dividends	417,514	304,653
Convertible notes payable, net of discount		443,700
TOTAL CURRENT LIABILITIES	1,710,449	1,580,030
TOTAL LIABILITIES	1,710,449	1,580,030
Redeemable convertible preferred stock - Series A; $0.0001 par value, 1,500 authorized, 480 shares issued and outstanding (liquidation preference of $742,800 and $721,200) as of September 30, 2023 and December 31, 2022, respectively	742,800	721,200
STOCKHOLDERS’ DEFICIT
Common stock, $0.0001 par value, 300,000,000 shares authorized, 3,470,811 and 2,279,019 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively	347	228
Unearned deferred compensation	(1,391,259)	(187,329)
Additional paid-in capital	39,222,671	33,428,115
Accumulated deficit	(39,674,693)	(35,177,625)
TOTAL STOCKHOLDERS’ DEFICIT	(1,842,932)	(1,936,609)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	610,317	364,621
Series B Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred stock, value	2	2
Series E-1 Preferred Stock [Member]
STOCKHOLDERS’ DEFICIT
Preferred stock, value
Related Party [Member]
CURRENT LIABILITIES
Notes payable - related parties	$ 7,500	$ 7,500

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Temporary equity, par or stated value per share	$ 0.0001	$ 0.0001
Temporary equity, shares authorized	1,500	1,500
Temporary equity, shares issued	480	480
Temporary equity, shares outstanding	480	480
Temporary equity, liquidation preference	$ 742,800	$ 721,200
Common stock, par or stated value per share	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	3,470,811	2,279,019
Common stock, shares outstanding	3,470,811	2,279,019
Series B Preferred Stock [Member]
Preferred stock, par or stated value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	2,500	2,500
Preferred stock, shares issued	1,509	1,509
Preferred stock, shares outstanding	1,509	1,509
Preferred stock, liquidation preference, value	$ 1,926,468	$ 1,813,607
Series E-1 Preferred Stock [Member]
Preferred stock, par or stated value per share	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	8,500	8,500
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
REVENUES
OPERATING EXPENSES
Payroll and related expenses	275,273	773,387	881,655	2,321,508
Professional fees	444,463	108,841	1,352,962	966,251
General and administrative	75,033	86,916	209,116	255,687
Research and development expenses	364,343	245,853	1,019,143	704,902
Total Operating Expenses	1,159,112	1,214,997	3,462,876	4,248,348
LOSS FROM OPERATIONS	(1,159,112)	(1,214,997)	(3,462,876)	(4,248,348)
OTHER INCOME (EXPENSE)
Financing costs including interest	(5,182)	(18,744)	(48,412)	(57,084)
Inducement interest			(397,928)
Total Other Expense, net	(5,182)	(18,744)	(446,340)	(57,084)
Loss from operations before income taxes	(1,164,294)	(1,233,741)	(3,909,216)	(4,305,432)
INCOME TAXES
NET LOSS	(1,164,294)	(1,233,741)	(3,909,216)	(4,305,432)
PREFERRED STOCK
Series A preferred contractual dividends	(7,200)	(7,200)	(21,600)	(20,420)
Series B preferred contractual dividends	(37,620)	(38,034)	(112,861)	(113,276)
Deemed dividends from Series A and B conversion price reduction	(40,461)		(305,541)
Deemed dividend on warrant modification			(282,309)	(41,225)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (1,249,575)	$ (1,278,975)	$ (4,631,527)	$ (4,480,353)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS: BASIC	$ (0.36)	$ (0.75)	$ (1.60)	$ (2.66)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS: DILUTED	$ (0.36)	$ (0.75)	$ (1.60)	$ (2.66)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: BASIC	3,452,023	1,699,444	2,896,643	1,685,074
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING: DILUTED	3,452,023	1,699,444	2,896,643	1,685,074

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member] Series E-1 Preferred Stock [Member]	Common Stock [Member]	Deferred Stock Based Compensation [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Series B Preferred Stock [Member]	Total
Balance at Dec. 31, 2021	$ 2		$ 165	$ (900,742)	$ 29,765,585	$ (29,281,674)		$ (416,664)
Balance, shares at Dec. 31, 2021	1,509		1,652,102
Common stock issued for services			$ 3		254,748			254,751
Common stock issused for services, shares			28,750
Conversion of debentures			$ 1		34,999			35,000
Conversion of debentures, shares			5,469
Incremental value from warrant modifications					41,225	(41,225)
Series A, preferred stock contractual dividends					(7,202)			(7,202)
40:1 Reverse Split Fractional Shares Adjustment
40:1 Reverse Split Fractional Shares Adjustment, shares			266
Series B, preferred stock contractual dividends					(37,206)			(37,206)
Accretion of stock-based compensation to employees and directors				213,041	107,312			320,353
Accretion of stock-based compensation to employees and directors, shares
Net loss period						(1,788,246)		(1,788,246)
Balance at Mar. 31, 2022	$ 2		$ 169	(687,701)	30,159,461	(31,111,145)		(1,639,214)
Balance, shares at Mar. 31, 2022	1,509		1,686,587
Balance at Dec. 31, 2021	$ 2		$ 165	(900,742)	29,765,585	(29,281,674)		(416,664)
Balance, shares at Dec. 31, 2021	1,509		1,652,102
Net loss period								$ (4,305,432)
Issuance of common stock for cash, shares								269,775
Balance at Sep. 30, 2022			$ 193	(348,548)	31,563,286	(33,628,332)		$ (2,413,399)
Balance, shares at Sep. 30, 2022	1,509		1,922,143
Balance at Mar. 31, 2022	$ 2		$ 169	(687,701)	30,159,461	(31,111,145)		(1,639,214)
Balance, shares at Mar. 31, 2022	1,509		1,686,587
Series A, preferred stock contractual dividends					(6,018)			(6,018)
Series B, preferred stock contractual dividends					(38,035)			(38,035)
Accretion of stock-based compensation to employees and directors				215,409	212,175			427,584
Net loss period						(1,283,446)		(1,283,446)
Balance at Jun. 30, 2022			$ 169	(472,292)	30,327,583	(32,394,591)		(2,539,129)
Balance, shares at Jun. 30, 2022	1,509		1,686,587
Series A, preferred stock contractual dividends					(7,200)			(7,200)
Series B, preferred stock contractual dividends					(38,034)			(38,034)
Accretion of stock-based compensation to employees and directors				217,776	190,961			408,737
Net loss period						(1,233,741)		(1,233,741)
Stock-based compensation for services			$ 3	(94,032)	164,997			70,968
Stock-based compensation for services, shares			30,000
Sale of common stock and warrants			$ 21		924,979			925,000
Sale of common stock and warrants, shares			205,556
Balance at Sep. 30, 2022			$ 193	(348,548)	31,563,286	(33,628,332)		(2,413,399)
Balance, shares at Sep. 30, 2022	1,509		1,922,143
Balance at Dec. 31, 2022	$ 2		$ 228	(187,329)	33,428,115	(35,177,625)		(1,936,609)
Balance, shares at Dec. 31, 2022	1,509		2,279,019
Common stock issued for services			$ 2	115,090	141,477			256,569
Common stock issused for services, shares			16,500
Incremental value from warrant modifications					282,309	(282,309)
Series A, preferred stock contractual dividends					(7,200)			(7,200)
Series B, preferred stock contractual dividends					(37,207)			(37,207)
Accretion of stock-based compensation to employees and directors				36,740	132,593			169,333
Net loss period						(1,507,042)		(1,507,042)
Deemed dividend from Series A conversion price adjustment					96,245	(96,245)
Deemed dividend from Series B conversion price adjustment					168,835	(168,835)
Issuance of common stock for cash			$ 7		314,239			314,246
Issuance of common stock for cash, shares			69,834
Exercise of warrants for cash to common stock			$ 37		1,094,965			1,095,001
Exercise of warrants for cash to common stock, shares			365,001
Conversion of convertible debt to common stock			$ 16		519,696			519,712
Conversion of convertible debt to common stock, shares			164,446
Inducement for conversion of convertible debt					397,937			397,937
Balance at Mar. 31, 2023	$ 2		$ 290	(35,499)	36,532,003	(37,232,056)		(735,260)
Balance, shares at Mar. 31, 2023	1,509		2,894,800
Balance at Dec. 31, 2022	$ 2		$ 228	(187,329)	33,428,115	(35,177,625)		(1,936,609)
Balance, shares at Dec. 31, 2022	1,509		2,279,019
Net loss period								$ (3,909,216)
Issuance of common stock for cash							$ 642,018
Issuance of common stock for cash, shares								1,191,792
Balance at Sep. 30, 2023	$ 2		$ 347	(1,391,259)	39,222,671	(39,674,693)		$ (1,842,932)
Balance, shares at Sep. 30, 2023	1,509		3,470,811
Balance at Mar. 31, 2023	$ 2		$ 290	(35,499)	36,532,003	(37,232,056)		(735,260)
Balance, shares at Mar. 31, 2023	1,509		2,894,800
Common stock issued for services			$ 7	(78,875)	323,482			244,614
Common stock issused for services, shares			76,000
Series A, preferred stock contractual dividends					(7,200)			(7,200)
Series B, preferred stock contractual dividends					(37,620)			(37,620)
Accretion of stock-based compensation to employees and directors			$ 27	(1,345,510)	1,467,953			122,470
Accretion of stock-based compensation to employees and directors, shares			271,141
Net loss period						(1,237,882)		(1,237,882)
Balance at Jun. 30, 2023	$ 2		$ 324	(1,459,884)	38,278,618	(38,469,938)		(1,650,878)
Balance, shares at Jun. 30, 2023	1,509		3,241,941
Common stock issued for services			$ 5	68,625	235,366			303,996
Common stock issused for services, shares			52,400
Series A, preferred stock contractual dividends					(7,200)			(7,200)
Series B, preferred stock contractual dividends					(38,034)			(38,034)
Accretion of stock-based compensation to employees and directors					113,478			113,478
Net loss period						(1,164,294)		(1,164,294)
Issuance of common stock for cash			$ 18		599,982			600,000
Issuance of common stock for cash, shares			176,470
Balance at Sep. 30, 2023	$ 2		$ 347	$ (1,391,259)	$ 39,222,671	$ (39,674,693)		$ (1,842,932)
Balance, shares at Sep. 30, 2023	1,509		3,470,811

Consolidated Statements of St_2

Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) (Parenthetical)			3 Months Ended
	Mar. 09, 2022	Mar. 04, 2022	Mar. 31, 2022
Statement of Stockholders' Equity [Abstract]
Reverse stock split	all shares adjusted to reflect a 40:1 reverse stock split	Company completed a 40:1 reverse stock split of its common shares.	40:1 Reverse Split

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net Loss	$ (3,909,216)	$ (4,305,432)
Adjustments to reconcile net loss to net cash used in operations:
Common stock issued for services	805,129	325,719
Stock-based compensation to employees and directors	395,107	1,156,674
Amortization of debt discount	36,332	27,225
Inducement expense	397,928
Changes in operating assets and liabilities
Decrease in prepaid expenses and other current assets	75,621	68,855
Increase in accounts payable and accrued expenses	504,126	451,329
Increase in accrued payroll and related expenses		715,054
Increase in accrued interest	7,043
Net cash used in operating activities	(1,687,930)	(1,560,576)
CASH FLOWS FROM FINANCING ACTIVITIES
Deferred offering costs		35,000
Proceeds from warrant exercise	1,095,001
Proceeds from sale of common stock and warrants	814,246	925,000
Net cash provided by financing activities	1,909,247	960,000
NET INCREASE (DECREASE) IN CASH	221,317	(600,576)
CASH - Beginning of period	225,276	1,499,866
CASH - End of period	446,593	899,290
SUPPLEMENTAL CASH FLOW DISCLOSURES:
Payment of interest in cash
Payment of income taxes
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Accrual of contractual dividends on Series A convertible preferred stock	21,600	20,420
Accrual of contractual dividends on Series B convertible preferred stock	112,861	113,276
Deemed dividend on warrant modifications	282,309	41,225
Incremental value of Series A conversion modifications	96,245
Incremental value of Series B conversion modifications	209,296
Deferred compensation for employees and consultants	1,468,510
Subscription receivable	100,000
Conversion of notes payable to common stock	$ 519,712

ORGANIZATION AND DESCRIPTION OF

ORGANIZATION AND DESCRIPTION OF BUSINESS	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS QSAM Biosciences Inc. (hereinafter the “Company”, “we”, “our”, “us”), incorporated in Delaware on August 26, 2004, is currently engaged in the business of developing a novel radiopharmaceutical drug candidate for the treatment of bone cancer. This business line commenced in earnest in the fourth fiscal quarter of 2020 as a result of the separation and transfer pursuant to an Omnibus Separation Agreement dated November 6, 2020 (the “Separation Agreement”) of the Company’s prior business in a separate sector (the “Legacy Business”) through an unconsolidated investee entity called Earth Property Holdings LLC, a Delaware limited liability company (“EPH”). Pursuant to the Separation Agreement, the Company transferred to EPH all assets and related liabilities in connection with the Legacy Business in return for a forgiveness of debt. The Company sold its entire equity interest in EPH to a third party in the first quarter of 2021 for $ 100,000 In April 2020, the Company established QSAM Therapeutics Inc. (“QSAM”) as a wholly-owned subsidiary incorporated in the state of Texas, and through QSAM, executed a Patent and Technology License Agreement and Trademark Assignment (the “License Agreement”) with IGL Pharma, Inc. (“IGL”). The License Agreement provides QSAM with exclusive, worldwide and sub-licensable rights to all of IGL’s patents, product data and knowhow with respect to Samaium-153 DOTMP aka CycloSam® (the “Technology”), a clinical stage novel radiopharmaceutical meant to treat different types of bone cancer. In connection with the transition to the life sciences sector, the Company changed its name to QSAM Biosciences Inc. on September 4, 2020, and subsequently changed its stock symbol to QSAM, to better reflect its business moving forward. On March 4, 2022, the Company completed a 40:1 reverse stock split of its common shares.

BASIS OF PRESENTATION AND GOING

BASIS OF PRESENTATION AND GOING CONCERN	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION AND GOING CONCERN	NOTE 2 – BASIS OF PRESENTATION AND GOING CONCERN The accompanying unaudited financial statements are prepared in accordance with Rule 8-01 of Regulation S-X of the Securities Exchange Commission (“SEC”). Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) have been condensed or omitted pursuant to such rules and regulations. However, the Company believes that the disclosures included in these unaudited consolidated financial statements are adequate to make the information presented not misleading. The unaudited consolidated financial statements included in this document have been prepared on the same basis as the annual financial statements, and in our opinion reflect all adjustments, which include normal recurring adjustments necessary for a fair presentation in accordance with US GAAP and SEC regulations for interim financial statements. The results for the three and nine months ended September 30, 2023 are not necessarily indicative of the results that the Company will have for any subsequent period or for the calendar year ended December 31, 2023. These unaudited consolidated financial statements should be read in conjunction with the audited financial statements and the notes to those statements for the year ended December 31, 2022 which was filed with the SEC on March 30, 2023. For the nine months ended September 30, 2023, the Company used net cash in operating activities for its operations of $ 1,687,930 3,909,216 1,100,132 446,593 39,674,693 The Company has supported operations through the issuance of common stock, preferred stock and debt over the last 12 months. This includes a common stock and warrant offering which closed March 31, 2023, of which a total of $ 2.85 342,667 600,000 100,000 Management expects expenses to increase through the end of 2023 and into 2024 as our drug technology continues through clinical trials, and as a result, we will need to raise additional capital to support these operations. Management believes that it can do so through equity or debt raises in the fourth quarter of 2023 or first half of 2024. If the Company is not successful in raising additional capital, it may need to delay clinical trials, reduce overhead, or in the most extreme scenario, shut down operations. There is no guarantee whether the Company will be able to generate revenue and/or raise capital sufficient to support its continuing operations. The ability of the Company to continue as a going concern is dependent on management’s plans which include implementation of its business model to develop and commercialize its drug candidate, seek strategic partnerships to advance clinical trials and other research endeavors which could provide additional capital to the Company, and continue to raise funds for the Company through equity or debt offerings. There is no assurance, however, that the Company will be successful in raising the needed capital and, if funding is available, that it will be available on terms acceptable to the Company. The unaudited consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The unaudited consolidated financial statements include the accounts of QSAM Biosciences Inc. and its wholly-owned subsidiaries (the “Subsidiaries”) QSAM Therapeutics Inc. and Q2Power Corp. (currently inactive). All significant inter-company transactions and balances have been eliminated in consolidation. References herein to the Company include the Company and its Subsidiaries unless the context otherwise requires. Cash and Cash Equivalents The Company considers cash, short-term deposits, and other investments with original maturities of no more than ninety days when acquired to be cash and cash equivalents for the purposes of the statement of cash flows. The Company maintains cash balances at one national financial institution and has experienced no losses with respect to amounts on deposit. Any loss incurred or a lack of access to such funds above the FDIC limit could have a significant adverse impact on the Company’s financial condition, results of operations and cash flows. The Company held no Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 606, “Revenue from Contracts with Customers (“ASC 606”) and all the related amendments. The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than previously required under U.S. GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company had no Stock Based Compensation The Company applies the fair value method of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718, “ Share Based Payment The Black-Scholes option pricing valuation method is used to determine fair value of stock options consistent with ASC 718, “ Share Based Payment”. Research and Development Research and development costs are expensed as incurred. Research and development costs were $ 1,019,143 704,902 Income Taxes Income taxes are accounted for under the asset and liability method as stipulated by FASB ASC 740, “ Income Taxes A valuation allowance is applied when in management’s view it is more likely than not (50%) that such deferred tax will not be utilized. In the event that an uncertain tax position exists in which the Company could incur income taxes, the Company would evaluate whether there is a probability that the uncertain tax position taken would be sustained upon examination by the taxing authorities. Reserves for uncertain tax positions would be recorded if the Company determined it is probable that a position would not be sustained upon examination or if payment would have to be made to a taxing authority and the amount is reasonably estimated. As of September 30, 2023 and December 31, 2022, the Company does not believe it has any uncertain tax positions that would result in the Company having a liability to the taxing authorities. Interest and penalties related to any unrecognized tax benefits is recognized in the unaudited consolidated financial statements as a component of income taxes. Basic and Diluted Loss Per Share Net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period plus any potentially dilutive shares related to the issuance of stock options, shares from the issuance of stock warrants, shares issued from the conversion of convertible preferred stock and shares issued for the conversion of convertible debt. As of September 30, 2023, there were the following potentially dilutive securities that were excluded from diluted net loss per share because their effect would be anti-dilutive ( all shares adjusted to reflect a 40:1 reverse stock split SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE Shares from common stock options 177,815 Shares from common stock warrants 50,000 Shares from the conversion of Series A Stock inclusive of cumulative dividends 246,544 Shares from the conversion of Series B Preferred Stock inclusive of dividends (1) 363,485 837,844 (1) Pursuant to agreements signed in October 2023 with the Series B Stockholders, upon a listing of the Company’s stock on Nasdaq or the signing of an agreement to sell or merger the Company, these stockholders will automatically exchange all of their shares of Series B Stock including accrued dividends through September 30, 2023 for a total of 642,018 As of September 30, 2022, there were the following potentially dilutive securities that were excluded from diluted net loss per share because their effect would be anti-dilutive ( all shares adjusted to reflect a 40:1 reverse stock split Shares from common stock options 177,815 Shares from common stock warrants 242,639 Shares from the conversion of convertible notes and accrued interest 79,727 Shares from the conversion of Series A Stock inclusive of cumulative dividends 111,563 Shares from the conversion of Series B Preferred Stock inclusive of dividends 271,490 883,234 Significant Estimates U.S. Generally Accepted Accounting Principles (“GAAP”) requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited financial statements, the reported amounts of revenues and expenses, cash flows and the related footnote disclosures during the period. On an on-going basis, the Company reviews and evaluates its estimates and assumptions, including, but not limited to, those that relate to the fair value of stock-based compensation, and a valuation allowance on deferred tax assets. Actual results could differ from these estimates. Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2022 for public business entities that are not smaller reporting companies and for all other entities, fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The standard should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. Effective January 1, 2021, the Company adopted ASU 2020-06 and noted no material impact to the consolidated financial statements. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on its unaudited financial statements. Concentration of Risk The Company expects cash to be the asset most likely to subject the Company to concentrations of credit risk. The Company’s bank deposits may at times exceed federally insured limits. The Company’s policy is to maintain its cash with high credit quality financial institutions to limit its risk of loss exposure. The Company’s cash balance as of September 30, 2023 is in excess of FDIC limits in the amount of approximately $ 196,593 The Company is subject to a number of risks similar to those of other companies at a clinical-stage for radiopharmaceutical drug candidates, including dependence on key individuals; the need to develop commercially viable therapeutics; competition from other companies, many of which are larger and better capitalized; intellectual property risks; and the need to obtain adequate additional financing to fund the development of its products. The Company currently depends on third-party suppliers for key materials and services used in its research and development manufacturing process, and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services. The Company’s primary Technology is licensed from one party and is subject to general risks related to contractual relationships and the performance of the parties under the contract. Fair Value of Financial Instruments In accordance with Accounting Standards Codification (“ASC”) 825, Financial Instruments Other financial instruments, including accounts payable, accrued liabilities and short-term debt, are carried at cost, which approximates fair value given their short-term nature. Deferred Offering Cost Costs incurred prior to an equity offering are capitalized until the offering occurs. Upon the equity offering, all accumulated costs are charged against proceeds. If the Company determines that the equity offering will not occur, the accumulated costs are charged to operations. Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company views its operations and manages its business as one

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 4 – RELATED PARTY TRANSACTIONS The Company has a License Agreement with IGL Pharma, Inc. (“IGL”), an entity in which the Company’s Executive Chairman serves as President, holds options to purchase less than a 1 500 0 9,355 0 13,900 During the year ended December 31, 2020, the Company received $ 45,500 10 7,500 During 2022, the Company started accruing compensation for the Board of Directors. Each board member receives an annual retainer of $ 30,000 annual fees of $ 20,000 15,000 10,000 7,500 5,000 3,500 185,438 101,991 As of September 30, 2023, the Company raised $ 600,000 100,000

CONVERTIBLE PROMISSORY NOTES

CONVERTIBLE PROMISSORY NOTES	9 Months Ended
	Sep. 30, 2023
Convertible Promissory Notes
CONVERTIBLE PROMISSORY NOTES	NOTE 5 – CONVERTIBLE PROMISSORY NOTES Convertible Notes Payable In the fourth quarter of 2021, the Company issued a total of $ 605,000 186,601 December 31, 2023 6 24.00 72,600 In the fourth quarter of 2022, two note holders converted $ 132,932 22,155 6.00 519,712 148,621 3.50 15,825 397,937 594,484 4.00 During the nine-month periods ended September 30, 2023 and 2022, the Company recorded interest expense related to the amortization of the discount of $ 36,300 27,225 0 36,300

TEMPORARY EQUITY, PREFERRED STO

TEMPORARY EQUITY, PREFERRED STOCK, COMMON STOCK, AND WARRANTS	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
TEMPORARY EQUITY, PREFERRED STOCK, COMMON STOCK, AND WARRANTS	NOTE 6 – TEMPORARY EQUITY, PREFERRED STOCK, COMMON STOCK, AND WARRANTS Series A Redeemable Convertible Preferred Stock (“Series A Stock”) As of September 30, 2023 and December 31, 2022, the Company has 480 480,000 The Series A Stock carries a 6 262,800 241,200 742,800 721,200 The outstanding principal and accrued dividends on the shares of Series A Stock as of September 30, 2023 are convertible into the Company’s common stock at $ 3.00 3.33 3.00 96,245 4.00 Prior to the recent Conversion Price adjustment, the outstanding shares of Series A Stock as of December 31, 2022 were convertible at $ 3.33 4.50 3.33 6.40 3.33 342,497 3.33 Management has determined that the Series A Stock is more akin to a debt security than equity primarily because it contains a mandatory 2-year redemption date at the option of the holder (which pursuant to a March 31, 2023 modification signed by both Series A Stockholders, was changed to December 31, 2023 from March 31, 2023), which only occurs if the Series A Stock is not converted to common stock. Therefore, management has presented the Series A Stock outside of permanent equity as mezzanine equity, which resides between liabilities and equity. Series B Convertible Preferred Stock (“Series B Stock”) In December 2020, the Company filed an amendment to its Articles of Incorporation to authorize the issuance of up to 2,500 0.001 10 1,000 1,000 2,500,000 156,000 23,000 991 163,134 53,061 1,509 417,514 304,653 The Series B Stock was originally convertible into common stock at a ratio of $ 6.40 6.19 6.40 6.19 30,938 For the three-month period ended March 31, 2023, the anti-dilution protections were triggered as a result of additional common stock issuances and the warrant conversion repricing, and the conversion ratio was reduced to $ 5.42 6.19 5.42 168,835 For the three-month period ended September 30, 2023, the anti-dilution protections were triggered as a result of additional common stock issuances, and the conversion ratio was reduced to $ 5.30 5.42 5.30 40,461 As of October 31, 2023, all remaining Series B Stockholders have signed agreements with the Company providing that if the Company lists its common shares on Nasdaq or otherwise signs an agreement to be acquired, such shareholders will automatically and without any further action on their part exchange their shares of Series B Stock into common shares at an exchange ratio of $ 3.00 Series E-1 Preferred Stock (“Series E-1 Stock”) On December 3, 2020, the Company filed an amendment to its Articles of Incorporation to authorize the issuance of up to 8,500 The shares of Series E-1 Stock were incentive-based, vesting and forfeitable securities that were issued to the Company’s executives and one director. The Series E-1 Stock also provided the holders the right in the aggregate to receive an “earnout” equal to 20% of the total consideration received by the Company in the instance of a sale or sub-license of its core licensed radiopharmaceutical Technology, or sale or merger of the Company, which was to be paid on a priority, senior basis, as well as other conversion and voting rights. On December 6, 2021, the Company entered into an Exchange Agreement and Plan of Reorganization (the “Exchange Agreement”) with all Series E-1 Stockholders pursuant to which all shares of Series E-1 Stock were exchanged into an aggregate of 720,986 8.65 12.00 720,986 For the nine-month periods ending September 30, 2023 and 2022, the Company recognized stock-based compensation to employees and directors totaling $ 0 428,450 Common Stock In 2022, the Company effected a 40:1 reverse stock split During the nine-month periods ended September 30, 2023 and 2022, the Company issued shares of common stock as follows: SCHEDULE OF ISSUED SHARES OF COMMON STOCK 2023 2022 For the nine months ended 2023 2022 Conversion of debentures and accrued interest - 5,469 Exercise of common stock warrants to common stock 365,001 - Stock based compensation to employees and directors 271,141 - Stock based compensation for services performed by one prior director - 10,000 Conversion of convertible debt to common stock, including “make whole” issuances 164,446 - Issuance of common stock for cash 246,304 205,556 Stock based compensation for services 144,900 48,750 Total common shares issued 1,191,792 269,775 During the nine-month period ended September 30, 2023, the Company issued 69,834 314,251 176,471 600,000 100,000 480,000 519,712 164,446 3.50 365,001 365,001 3.00 1,144,501 49,500 342,669 Additionally during the nine-month period ended September 30, 2023, the Company issued 269,102 (1) 209,102 shares were issued as incentive compensation vesting 50% upon the Company’s uplisting to Nasdaq if within three years, with the balance vesting in eight quarterly installments commencing on the sooner of such Nasdaq uplisting or 12 months after issuance; provided all shares shall vest upon the sale, merger or other “exit” event for the Company and its shareholders; and (2) 60,000 shares were issued to compensate four members of the management team for acceptance of a significant reduction in their base salaries in 2023 to help the Company conserve cash resources, and vest upon the completion of the Company’s next funding in the amount of at least $5 million or Company exit. The awards scheduled to vest upon the occurrence of the vesting conditions will not vest in accordance with those vesting conditions if the recipient of the award is no longer providing services to the Company at the time of vesting. The award recipient’s status will end on the day the notice of terminiation is provided (whether by the Company or by the Participant upon resignation) and will not be extended by any notice period that may be required contractually or under applicable local law. Further, the Company issued 2,040 10,200 In connection with these awards, the Board of Directors approved for 2023 an increase in the total number of shares authorized under the 2016 Omnibus Equity Incentive Plan (the “2016 Plan”) by 350,000 106,000 During the nine-month period ended September 30, 2022, $ 35,000 5,469 6.40 48,750 10,000 205,556 Warrants During the nine-month period ended September 30, 2023, the Company issued 69,834 50,000 91,979 A summary of warrant activity and related information for the period ending September 30, 2023 is as follows: SCHEDULE OF ALL OUTSTANDING COMMON STOCK WARRANTS Warrants Weighted Aggregate Outstanding as of December 31, 2022 323,543 $ 6.15 $ - Issued 119,832 4.25 - Exercised 381,500 3.00 - Expired 11,875 10.00 - Outstanding as of September 30, 2023 50,000 $ 6.00 $ - The aggregate intrinsic value of the warrants is the difference between the fair market value of the Company’s closing price of its common stock at each reporting date, less the exercise price multiplied by the number of warrants outstanding, which was $ 0 The following is a summary of the outstanding common stock warrants as of September 30, 2023: SCHEDULE OF STOCKHOLDERS’ EQUITY NOTE WARRANTS OR RIGHTS Number of Exercise price Expiration Warrants issued in connection services agreement 50,000 $ 6.00 January 15, 2025 Total outstanding as of September 30, 2023 50,000

STOCK OPTIONS

STOCK OPTIONS	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
STOCK OPTIONS	NOTE 7 – STOCK OPTIONS In 2016 to compensate officers, directors and other key service providers with equity grants, the Board approved the 2016 Omnibus Equity Incentive Plan (“2016 Plan”), which initially allowed for 4,000 550,000 105,898 5 The Company has not issued any stock options during the three and nine-month period ended September 30, 2023; however, it did issue 269,102 A summary of stock option activity and related information during the nine-month period ended September 30, 2023 is as follows: SUMMARY OF STOCK OPTION ACTIVITY Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding as of December 31, 2022 177,815 $ 12.57 8.8 $ - Granted - $ - - $ - Outstanding as of September 30, 2023 177,815 $ 12.57 8.06 $ - The Company recorded $ 395,083 1,156,675 The aggregate intrinsic value of options is the difference between the fair market value of the Company’s closing price of its common stock at each reporting date, less the exercise price multiplied by the number of options granted, which was $ 0 As of September 30, 2023, there was unrecognized stock-based compensation of $ 279,895 We estimate the fair value of stock-based awards on the date of grant using the Black-Scholes option pricing model using the fair market value of our common stock on the date of grant and a number of other assumptions. These assumptions include estimates regarding the expected term of the awards, estimates of the stock volatility over a duration that approximates the expected term of the awards, estimates of the risk-free rate, and estimates of expected dividend rates.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 8 – COMMITMENTS AND CONTINGENCIES Employment Agreements The employment agreements as amended for the Company’s Executive Chairman and CEO each contain termination provisions whereby if they are terminated without cause or following a material change, as defined therein, they will receive salary through the date of termination plus an additional 24 months, bonus that would be earned during the full year when the termination became effective (or a lump sum of 50% of the full target bonus), all stock options shall vest and healthcare benefits will continue for 24 months. The Company’s General Counsel’s employment agreement, as amended, contains an 18-month severance payment in the instance of a termination without cause or following a material change, as defined therein. In June 2023, the Company’s General Counsel was provided the additional title of Executive Vice President – Corporate Development. Pursuant to amendments dated November 14, 2022 to the three employment agreements of the Company’s Executive Chairman, CEO and EVP/General Counsel, as well as an amendment to the employment agreement for the Company’s VP Operations (the “2022 Amendments”), each of these four employees have agreed to accept reduced salaries until the Company is successful in raising additional funds. Specifically, when the Company raises at least $7.5 million in a single offering, each employee’s salary will be increased to the full contracted rate; and prior to that time, the reduced salaries will be gradually increased as the Company raises $2 million and then $5 million. During this time, the difference between the reduced salaries and the full contracted salaries will not accrue as liabilities for the Company. Pursuant to the 2022 Amendments, $ 758,748 606,998 151,750 79,166 168,611 3.55 The shares of common stock issued pursuant to the 2022 Amendments are restricted and shall be subject to forfeiture as follows: until such time that the Company successfully closes $ 5 The employment agreements, as amended, for the Company’s Executive Chairman and CEO each contain a transaction bonus in the instance any of the Company’s assets are sold or sublicensed or if the Company or its subsidiary is acquired, equal to 1.75% of the consideration received by the Company. The employment agreement, as amended, for the Company’s EVP/General Counsel and for its VP Operations each contain a similar transaction bonus equal to 1.0% of consideration received by the Company, pursuant to a Board consent authorized and approved as of July 26, 2023. Pursuant to Board resolutions as of August 21, 2023, one of our directors was awarded a similar transaction bonus equal to 0.75% to compensate him for services he previously performed for the Company as interim medical director. Board of Director Agreements In January 2022, Adriann Sax was appointed as a Director to the Board and awarded an annual retainer of $ 30,000 7,500 10,000 85,104 43,542 In February 2022, Charles J. Link, Jr. was appointed as a Director to the Board and awarded an annual retainer of $ 30,000 7,500 15,000 3,500 100,333 51,333 In May 2023, each of Ms. Sax and Dr. Link received 10,455 These shares vest 50% upon a Nasdaq listing of the Company’s stock if completed within three years, and 50% in eight quarterly installments upon the sooner of the Nasdaq listing or 12 months from issuance. All shares will vest upon the sale, merger or other “exit” event of the Company. Pursuant to Board resolutions as of August 21, 2023, Dr. Link was awarded a transaction bonus in the instance any of the Company’s assets are sold or sublicensed or if the Company or its subsidiary is acquired, equal to 0.75% of the consideration received by the Company, to compensate him for services he previously performed for the Company as interim medical director. License Agreement The License Agreement for the Technology, as amended, between the Company’s wholly-owned subsidiary QSAM Therapeutics and IGL is for 20 410,000 ® 2 12,500 4.5 5 In connection with the License Agreement, QSAM signed a two-year Consulting and Confidentiality Agreement (the “Consulting Agreement”) with IGL, which provided IGL with payments of $ 8,500 8,500 During the nine-month period ending September 30, 2023, the Company paid $ 64,136.50 in expense reimbursements required under the ISO agreement. The drug development costs to IGL which has been reflected as research and development expense on the consolidated statements of operations was $ 0 and $ 95,988 for the period ending September 30, 2023 and June 30, 2022, respectively. As of September 30, 2023, $ 7,283 On July 1, 2022, QSAM signed a new work order under the Master Services Agreement dated August 31, 2020 with IsoTherapeutics Group, Inc. (“ISO”), a company that has common ownership control with IGL. The new work order with ISO is a $ 8,500

CORRECTION OF JUNE 30, 2023 FIN

CORRECTION OF JUNE 30, 2023 FINANCIAL STATEMENTS	9 Months Ended
	Sep. 30, 2023
Accounting Changes and Error Corrections [Abstract]
CORRECTION OF JUNE 30, 2023 FINANCIAL STATEMENTS	NOTE 9 – CORRECTION OF JUNE 30, 2023 FINANCIAL STATEMENTS The Consolidated Statement of Operations for the six month period ended June 30, 2023 previously issued contained an error in the following line items: Net Loss Attributable to Common Stockholders and the Basic and Diluted net loss attributable to common stockholders. The Company recorded deemed dividends on warrant modification and Series A Stock and Series B Stock conversion price reductions during the three month period ending March 31, 2023, and properly reflected those items as additional expenses added to Net Loss to arrive at Net Loss Attributable to Common Stockholders in the Consolidated Statement of Operations for the March 31, 2023 period. However, these deemed dividends were inadvertently omitted from the Consolidated Statement of Operations for the six month period ending June 30, 2023, causing the reported Net Loss Attributable to Common Stockholders and the Basic and Diluted net loss attributable to common stockholders for the six month period to be understated. The correction increases the by $ 265,080 282,309 ($2,834,151) ($3,381,540) ($1.07) ($1.27) There was no effect on the Net Loss for the six month period ended June 30, 2023, no effect on any balances for the periods in 2022, and no effect on any balances for the three month period ended June 30, 2023. Further, the deemed dividends were presented properly as an increase in Additional Paid-In Capital and the Accumulated Deficit in the Consolidated Statements of Stockholders’ Equity (Deficit) for the six month period ended June 30, 2023 and the Consolidated Balance Sheet as of that date, and were described properly in the footnotes to the Consolidated Financial Statements for the June 30, 2023 period. The correction was made in accordance with the provisions of ASC topic 250 Accounting Changes and Error Corrections. The disclosure provision of ASC 250 requires a company that corrects an error to disclose that its previously issued financial statements have been corrected, a description of the nature of the error, the effect of the correction on each financial statement line item and any per share amount affected for each prior period presented, and the cumulative effect on retained earnings (deficit) in the statement of financial position as of the beginning of the earliest period presented.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Sep. 30, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10 – SUBSEQUENT EVENTS In October 2023, all remaining Series B Stockholders signed agreements with the Company providing that if the Company lists its common shares on Nasdaq or otherwise signs an agreement to be acquired or merged with another Company, such shareholders will automatically and without any further action on their part exchange their shares of Series B Stock into common shares at an exchange ratio of $ 3.00 642,018

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The unaudited consolidated financial statements include the accounts of QSAM Biosciences Inc. and its wholly-owned subsidiaries (the “Subsidiaries”) QSAM Therapeutics Inc. and Q2Power Corp. (currently inactive). All significant inter-company transactions and balances have been eliminated in consolidation. References herein to the Company include the Company and its Subsidiaries unless the context otherwise requires.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers cash, short-term deposits, and other investments with original maturities of no more than ninety days when acquired to be cash and cash equivalents for the purposes of the statement of cash flows. The Company maintains cash balances at one national financial institution and has experienced no losses with respect to amounts on deposit. Any loss incurred or a lack of access to such funds above the FDIC limit could have a significant adverse impact on the Company’s financial condition, results of operations and cash flows. The Company held no
Revenue Recognition	Revenue Recognition The Company recognizes revenue in accordance with ASC Topic 606, “Revenue from Contracts with Customers (“ASC 606”) and all the related amendments. The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than previously required under U.S. GAAP, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The Company had no
Stock Based Compensation	Stock Based Compensation The Company applies the fair value method of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718, “ Share Based Payment The Black-Scholes option pricing valuation method is used to determine fair value of stock options consistent with ASC 718, “ Share Based Payment”.
Research and Development	Research and Development Research and development costs are expensed as incurred. Research and development costs were $ 1,019,143 704,902
Income Taxes	Income Taxes Income taxes are accounted for under the asset and liability method as stipulated by FASB ASC 740, “ Income Taxes A valuation allowance is applied when in management’s view it is more likely than not (50%) that such deferred tax will not be utilized. In the event that an uncertain tax position exists in which the Company could incur income taxes, the Company would evaluate whether there is a probability that the uncertain tax position taken would be sustained upon examination by the taxing authorities. Reserves for uncertain tax positions would be recorded if the Company determined it is probable that a position would not be sustained upon examination or if payment would have to be made to a taxing authority and the amount is reasonably estimated. As of September 30, 2023 and December 31, 2022, the Company does not believe it has any uncertain tax positions that would result in the Company having a liability to the taxing authorities. Interest and penalties related to any unrecognized tax benefits is recognized in the unaudited consolidated financial statements as a component of income taxes.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share Net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period plus any potentially dilutive shares related to the issuance of stock options, shares from the issuance of stock warrants, shares issued from the conversion of convertible preferred stock and shares issued for the conversion of convertible debt. As of September 30, 2023, there were the following potentially dilutive securities that were excluded from diluted net loss per share because their effect would be anti-dilutive ( all shares adjusted to reflect a 40:1 reverse stock split SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE Shares from common stock options 177,815 Shares from common stock warrants 50,000 Shares from the conversion of Series A Stock inclusive of cumulative dividends 246,544 Shares from the conversion of Series B Preferred Stock inclusive of dividends (1) 363,485 837,844 (1) Pursuant to agreements signed in October 2023 with the Series B Stockholders, upon a listing of the Company’s stock on Nasdaq or the signing of an agreement to sell or merger the Company, these stockholders will automatically exchange all of their shares of Series B Stock including accrued dividends through September 30, 2023 for a total of 642,018 As of September 30, 2022, there were the following potentially dilutive securities that were excluded from diluted net loss per share because their effect would be anti-dilutive ( all shares adjusted to reflect a 40:1 reverse stock split Shares from common stock options 177,815 Shares from common stock warrants 242,639 Shares from the conversion of convertible notes and accrued interest 79,727 Shares from the conversion of Series A Stock inclusive of cumulative dividends 111,563 Shares from the conversion of Series B Preferred Stock inclusive of dividends 271,490 883,234
Significant Estimates	Significant Estimates U.S. Generally Accepted Accounting Principles (“GAAP”) requires the Company to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited financial statements, the reported amounts of revenues and expenses, cash flows and the related footnote disclosures during the period. On an on-going basis, the Company reviews and evaluates its estimates and assumptions, including, but not limited to, those that relate to the fair value of stock-based compensation, and a valuation allowance on deferred tax assets. Actual results could differ from these estimates.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”) to simplify accounting for certain financial instruments. ASU 2020-06 eliminates the current models that require separation of beneficial conversion and cash conversion features from convertible instruments and simplifies the derivative scope exception guidance pertaining to equity classification of contracts in an entity’s own equity. The new standard also introduces additional disclosures for convertible debt and freestanding instruments that are indexed to and settled in an entity’s own equity. ASU 2020-06 amends the diluted earnings per share guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective January 1, 2022 for public business entities that are not smaller reporting companies and for all other entities, fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The standard should be applied on a full or modified retrospective basis, with early adoption permitted beginning on January 1, 2021. Effective January 1, 2021, the Company adopted ASU 2020-06 and noted no material impact to the consolidated financial statements. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on its unaudited financial statements.
Concentration of Risk	Concentration of Risk The Company expects cash to be the asset most likely to subject the Company to concentrations of credit risk. The Company’s bank deposits may at times exceed federally insured limits. The Company’s policy is to maintain its cash with high credit quality financial institutions to limit its risk of loss exposure. The Company’s cash balance as of September 30, 2023 is in excess of FDIC limits in the amount of approximately $ 196,593 The Company is subject to a number of risks similar to those of other companies at a clinical-stage for radiopharmaceutical drug candidates, including dependence on key individuals; the need to develop commercially viable therapeutics; competition from other companies, many of which are larger and better capitalized; intellectual property risks; and the need to obtain adequate additional financing to fund the development of its products. The Company currently depends on third-party suppliers for key materials and services used in its research and development manufacturing process, and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate materials and services. The Company’s primary Technology is licensed from one party and is subject to general risks related to contractual relationships and the performance of the parties under the contract.
Fair Value of Financial Instruments	Fair Value of Financial Instruments In accordance with Accounting Standards Codification (“ASC”) 825, Financial Instruments Other financial instruments, including accounts payable, accrued liabilities and short-term debt, are carried at cost, which approximates fair value given their short-term nature.
Deferred Offering Cost	Deferred Offering Cost Costs incurred prior to an equity offering are capitalized until the offering occurs. Upon the equity offering, all accumulated costs are charged against proceeds. If the Company determines that the equity offering will not occur, the accumulated costs are charged to operations.
Segment Reporting	Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company views its operations and manages its business as one

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE	As of September 30, 2023, there were the following potentially dilutive securities that were excluded from diluted net loss per share because their effect would be anti-dilutive ( all shares adjusted to reflect a 40:1 reverse stock split SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE Shares from common stock options 177,815 Shares from common stock warrants 50,000 Shares from the conversion of Series A Stock inclusive of cumulative dividends 246,544 Shares from the conversion of Series B Preferred Stock inclusive of dividends (1) 363,485 837,844 (1) Pursuant to agreements signed in October 2023 with the Series B Stockholders, upon a listing of the Company’s stock on Nasdaq or the signing of an agreement to sell or merger the Company, these stockholders will automatically exchange all of their shares of Series B Stock including accrued dividends through September 30, 2023 for a total of 642,018 As of September 30, 2022, there were the following potentially dilutive securities that were excluded from diluted net loss per share because their effect would be anti-dilutive ( all shares adjusted to reflect a 40:1 reverse stock split Shares from common stock options 177,815 Shares from common stock warrants 242,639 Shares from the conversion of convertible notes and accrued interest 79,727 Shares from the conversion of Series A Stock inclusive of cumulative dividends 111,563 Shares from the conversion of Series B Preferred Stock inclusive of dividends 271,490 883,234

TEMPORARY EQUITY, PREFERRED S_2

TEMPORARY EQUITY, PREFERRED STOCK, COMMON STOCK, AND WARRANTS (Tables)	9 Months Ended
	Sep. 30, 2023
Equity [Abstract]
SCHEDULE OF ISSUED SHARES OF COMMON STOCK	During the nine-month periods ended September 30, 2023 and 2022, the Company issued shares of common stock as follows: SCHEDULE OF ISSUED SHARES OF COMMON STOCK 2023 2022 For the nine months ended 2023 2022 Conversion of debentures and accrued interest - 5,469 Exercise of common stock warrants to common stock 365,001 - Stock based compensation to employees and directors 271,141 - Stock based compensation for services performed by one prior director - 10,000 Conversion of convertible debt to common stock, including “make whole” issuances 164,446 - Issuance of common stock for cash 246,304 205,556 Stock based compensation for services 144,900 48,750 Total common shares issued 1,191,792 269,775
SCHEDULE OF ALL OUTSTANDING COMMON STOCK WARRANTS	A summary of warrant activity and related information for the period ending September 30, 2023 is as follows: SCHEDULE OF ALL OUTSTANDING COMMON STOCK WARRANTS Warrants Weighted Aggregate Outstanding as of December 31, 2022 323,543 $ 6.15 $ - Issued 119,832 4.25 - Exercised 381,500 3.00 - Expired 11,875 10.00 - Outstanding as of September 30, 2023 50,000 $ 6.00 $ -
SCHEDULE OF STOCKHOLDERS’ EQUITY NOTE WARRANTS OR RIGHTS	The following is a summary of the outstanding common stock warrants as of September 30, 2023: SCHEDULE OF STOCKHOLDERS’ EQUITY NOTE WARRANTS OR RIGHTS Number of Exercise price Expiration Warrants issued in connection services agreement 50,000 $ 6.00 January 15, 2025 Total outstanding as of September 30, 2023 50,000

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
SUMMARY OF STOCK OPTION ACTIVITY	A summary of stock option activity and related information during the nine-month period ended September 30, 2023 is as follows: SUMMARY OF STOCK OPTION ACTIVITY Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding as of December 31, 2022 177,815 $ 12.57 8.8 $ - Granted - $ - - $ - Outstanding as of September 30, 2023 177,815 $ 12.57 8.06 $ -

ORGANIZATION AND DESCRIPTION _2

ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative) - USD ($)			3 Months Ended
	Mar. 09, 2022	Mar. 04, 2022	Mar. 31, 2022	Mar. 31, 2021
Reverse stock split	all shares adjusted to reflect a 40:1 reverse stock split	Company completed a 40:1 reverse stock split of its common shares.	40:1 Reverse Split
Earth Property Holdings LLC [Member]
Proceeds from sale of equity interest				$ 100,000

BASIS OF PRESENTATION AND GOI_2

BASIS OF PRESENTATION AND GOING CONCERN (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended
	Oct. 31, 2023	Apr. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Net cash used in operating activities					$ 1,687,930	$ 1,560,576
Loss from operations			$ 1,164,294	$ 1,233,741	3,909,216	$ 4,305,432
Working capital			1,100,132		1,100,132
Cash			446,593		446,593		$ 225,276
Accumulated deficit			$ 39,674,693		$ 39,674,693		$ 35,177,625
Common Stock [Member] | Subsequent Event [Member]
Subscriptions receivables, value	$ 100,000
Proceeds from private placement	$ 600,000
Common Stock and Warrant [Member]
Proceeds for issuance		$ 2,850,000
Subscriptions receivables, value		$ 342,667

SCHEDULE OF ANTIDILUTIVE SECURI

SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares	9 Months Ended
	Sep. 30, 2023		Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities, shares	837,844		883,234
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities, shares	177,815		177,815
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities, shares	50,000		242,639
Conversion of Series A Stock Inclusive of Cumulative Dividends [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities, shares	246,544		111,563
Conversion of Series B Preferred Stock Inclusive of Dividends [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities, shares	363,485	[1]	271,490
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities, shares			79,727
[1]Pursuant to agreements signed in October 2023 with the Series B Stockholders, upon a listing of the Company’s stock on Nasdaq or the signing of an agreement to sell or merger the Company, these stockholders will automatically exchange all of their shares of Series B Stock including accrued dividends through September 30, 2023 for a total of 642,018

SCHEDULE OF ANTIDILUTIVE SECU_2

SCHEDULE OF ANTIDILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2023
Common stock issued	$ 600,000	$ 314,246
Series B Preferred Stock [Member]
Common stock issued			$ 642,018

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)			3 Months Ended			9 Months Ended
	Mar. 09, 2022	Mar. 04, 2022	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Mar. 31, 2022	Sep. 30, 2023 USD ($) Segment	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Accounting Policies [Abstract]
Cash equivalents			$ 0			$ 0		$ 0
Revenue
Research and development costs			364,343	$ 245,853		$ 1,019,143	$ 704,902
Income tax likely hood percentage, description						A valuation allowance is applied when in management’s view it is more likely than not (50%) that such deferred tax will not be utilized.
Reverse stock split description	all shares adjusted to reflect a 40:1 reverse stock split	Company completed a 40:1 reverse stock split of its common shares.			40:1 Reverse Split
Cash in excess of FDIC limits			$ 196,593			$ 196,593
Number of operating segments | Segment						1

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2020
Related Party Transaction [Line Items]
Research and development related expenses	$ 364,343		$ 245,853	$ 1,019,143	$ 704,902
Compensation expense						$ 30,000
Accrued director fees	185,438			185,438		101,991
Stock Issued During Period, Value, New Issues	600,000	$ 314,246
Private Placement [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Value, New Issues				600,000
Audit Committee [Member]
Related Party Transaction [Line Items]
Annual fees				7,500		20,000
Compensation Committee [Member]
Related Party Transaction [Line Items]
Annual fees				5,000		15,000
Nominating And Governance Committee [Member]
Related Party Transaction [Line Items]
Annual fees				3,500
IGL Pharma Inc [Member]
Related Party Transaction [Line Items]
Research and development related expenses	0		$ 9,355
IGL Pharma Inc [Member] | Service [Member]
Related Party Transaction [Line Items]
Due to related party	0			0		13,900
Officers and Directors [Member]
Related Party Transaction [Line Items]
Proceeds from short-term notes payable							$ 45,500
Bearing interest							10%
Short-term notes payable outstanding	7,500			7,500		7,500
Nominating And Governance Committee [Member]
Related Party Transaction [Line Items]
Annual fees						$ 10,000
Three Accredited Investors [Member]
Related Party Transaction [Line Items]
Investors	$ 100,000			$ 100,000
IGL Pharma Inc [Member] | President [Member]
Related Party Transaction [Line Items]
Non-controlling equity interest	1%			1%
Annual fees				$ 500

CONVERTIBLE PROMISSORY NOTES (D

CONVERTIBLE PROMISSORY NOTES (Details Narrative) - USD ($)	3 Months Ended			9 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2023	Sep. 30, 2022
Short-Term Debt [Line Items]
Value of notes converted				$ 519,712
Convertible Promissory Notes [Member]
Short-Term Debt [Line Items]
Proceeds from convertible notes payable			$ 605,000
Conversion for common stock	186,601
Maturity date			Dec. 31, 2023
Interest rate, stated percentage			6%
Stock price	$ 4		$ 24
Unamortized debt discount		$ 36,300		0
Value of notes converted	$ 519,712
Debt conversion, shares issued	148,621
Debt conversion price	$ 3.50
Inducement interest expense	$ 397,937
Fair value shares issued for the conversion	594,484
Interest expense on amortization of discount				$ 36,300	$ 27,225
Convertible Promissory Notes [Member] | Two Note Holders [Member]
Short-Term Debt [Line Items]
Value of notes converted		$ 132,932
Debt conversion, shares issued	15,825	22,155
Debt conversion price		$ 6
Convertible Promissory Notes [Member] | Warrant [Member]
Short-Term Debt [Line Items]
Unamortized debt discount			$ 72,600

SCHEDULE OF ISSUED SHARES OF CO

SCHEDULE OF ISSUED SHARES OF COMMON STOCK (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2023	Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total common shares issued			1,191,792	269,775
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total common shares issued	176,470	69,834
Common Stock [Member] | Conversion of Debentures and Accrued Interest [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total common shares issued				5,469
Common Stock [Member] | Exercise of Common Stock Warrants to Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total common shares issued			365,001
Common Stock [Member] | Stock Based Compensation to Employees and Directors [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total common shares issued			271,141
Common Stock [Member] | Stock Based Compensation for Services Performed by One Prior Director [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total common shares issued				10,000
Common Stock [Member] | Conversion of Convertible Debt to Common Stock, Including "Make Whole" Issuances [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total common shares issued			164,446
Common Stock [Member] | Issuance of Common Stock for Cash [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total common shares issued			246,304	205,556
Common Stock [Member] | Stock Based Compensation for Services [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Total common shares issued			144,900	48,750

SCHEDULE OF ALL OUTSTANDING COM

SCHEDULE OF ALL OUTSTANDING COMMON STOCK WARRANTS (Details) - Warrant [Member]	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants outstanding, Beginning | shares	323,543
Warrants Weighted Average Exercise Price, Beginning | $ / shares	$ 6.15
Warrants Aggregate Intrinsic Value, Beginning | $
Warrants Issued | shares	119,832
Warrants Weighted Average Exercise Price, Issued | $ / shares	$ 4.25
Warrants Aggregate Intrinsic Value, Issued | $
Warrants Exercised | shares	381,500
Warrants Weighted Average Exercise Price, Exercised | $ / shares	$ 3
Warrants Expired | shares	11,875
Warrants Weighted Average Exercise Price, Expired | $ / shares	$ 10
Warrants outstanding, Ending | shares	50,000
Warrants Weighted Average Exercise Price, Ending | $ / shares	$ 6
Warrants Aggregate Intrinsic Value, Ending | $

SCHEDULE OF STOCKHOLDERS_ EQUIT

SCHEDULE OF STOCKHOLDERS’ EQUITY NOTE WARRANTS OR RIGHTS (Details)	Sep. 30, 2023 $ / shares shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of Warrants Outstanding | shares	50,000
Warrants, Exercise price per share | $ / shares	$ 3
Warrants Issued in Connection Services Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of Warrants Outstanding | shares	50,000
Warrants, Exercise price per share | $ / shares	$ 6
Warrants, Expiration Date	Jan. 15, 2025

TEMPORARY EQUITY, PREFERRED S_3

TEMPORARY EQUITY, PREFERRED STOCK, COMMON STOCK, AND WARRANTS (Details Narrative) - USD ($)				1 Months Ended				3 Months Ended				9 Months Ended		12 Months Ended
	Mar. 09, 2022	Mar. 04, 2022	Dec. 06, 2021	Oct. 31, 2023	Aug. 24, 2021	Jan. 31, 2021	Dec. 31, 2020	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022	Dec. 03, 2020
Class of Stock [Line Items]
Temporary equity, shares issued								480				480		480
Temporary equity, shares outstanding								480				480		480
Temporary equity, liquidation preference								$ 742,800				$ 742,800		$ 721,200
Temporary equity, value								742,800				742,800		721,200
Recognized stock based compensation												$ 395,107	$ 1,156,674
Reverse stock split, description	all shares adjusted to reflect a 40:1 reverse stock split	Company completed a 40:1 reverse stock split of its common shares.									40:1 Reverse Split
Additional shares, issuance												1,191,792	269,775
Issuance of common stock for cash								600,000		$ 314,246
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable								$ 342,669				$ 342,669
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 3				$ 3
[custom:OffsetFees]												$ 49,500
Number of shares issues												205,556
Service [Member]
Class of Stock [Line Items]
Warrants issued								50,000				50,000
Number of warrants outstanding								$ 91,979				$ 91,979
2016 Plan [Member]
Class of Stock [Line Items]
Additional shares, issuance												350,000
Shares available for future issuance								106,000				106,000
Common Stock and Warrant Unit Offering [Member]
Class of Stock [Line Items]
Additional shares, issuance												69,834
Issuance of common stock for cash												$ 314,251
Warrants issued								69,834				69,834
Private Placement [Member]
Class of Stock [Line Items]
Additional shares, issuance												176,471
Issuance of common stock for cash												$ 600,000
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable								$ 100,000				$ 100,000
Board Members and Employees [Member]
Class of Stock [Line Items]
Additional shares, issuance												269,102
Share based compensation award, description												(1) 209,102 shares were issued as incentive compensation vesting 50% upon the Company’s uplisting to Nasdaq if within three years, with the balance vesting in eight quarterly installments commencing on the sooner of such Nasdaq uplisting or 12 months after issuance; provided all shares shall vest upon the sale, merger or other “exit” event for the Company and its shareholders; and (2) 60,000 shares were issued to compensate four members of the management team for acceptance of a significant reduction in their base salaries in 2023 to help the Company conserve cash resources, and vest upon the completion of the Company’s next funding in the amount of at least $5 million or Company exit. The awards scheduled to vest upon the occurrence of the vesting conditions will not vest in accordance with those vesting conditions if the recipient of the award is no longer providing services to the Company at the time of vesting. The award recipient’s status will end on the day the notice of terminiation is provided (whether by the Company or by the Participant upon resignation) and will not be extended by any notice period that may be required contractually or under applicable local law.
Chief Financial Officer [Member]
Class of Stock [Line Items]
Additional shares, issuance												2,040
Issuance of common stock for cash												$ 10,200
Common Stock [Member]
Class of Stock [Line Items]
Estimated fair value of common stock												$ 4
Debt conversion, original debt, amount										$ 480,000			$ 35,000
Additional shares, issuance								176,470		69,834
Issuance of common stock for cash								$ 18		$ 7
Interest and debt expense										$ 519,712
Debt conversion, shares issued										164,446			5,469
Debt conversion price										$ 3.50			$ 6.40
Shares of common stock								1,144,501				1,144,501
Additional stock issued for services													48,750
Stock issued during period shares, issued for services								52,400	76,000	16,500	28,750
Common Stock [Member] | Exercise of Common Stock Warrants to Common Stock [Member]
Class of Stock [Line Items]
Additional shares, issuance												365,001
Shares of common stock								365,001				365,001
Common Stock [Member] | Director [Member]
Class of Stock [Line Items]
Stock issued during period shares, issued for services													10,000
Warrant [Member]
Class of Stock [Line Items]
Number of warrants outstanding								$ 0				$ 0		$ 0
Warrant [Member] | Exercise of Common Stock Warrants to Common Stock [Member]
Class of Stock [Line Items]
Shares of common stock								365,001				365,001
Series A Stock [Member]
Class of Stock [Line Items]
Temporary equity, shares issued								480				480		480
Temporary equity, shares outstanding								480				480		480
Temporary equity, liquidation preference								$ 480,000				$ 480,000
Temporary equity, dividend rate												6%
Accrued dividends								262,800				$ 262,800		$ 241,200
Temporary equity, value								$ 742,800				$ 742,800		$ 721,200
Conversion price								$ 3				$ 3		$ 3.33
Incremental value due to the conversion price reduction								$ 96,245				$ 96,245		$ 342,497
Estimated fair value of common stock														$ 3.33
Series A Stock [Member] | Warrant [Member]
Class of Stock [Line Items]
Common stock issued per share														4.50
Series A Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Conversion price								$ 3.33				$ 3.33		6.40
Series A Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Conversion price								$ 3				$ 3		3.33
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Conversion price							$ 6.40							$ 6.19
Incremental value due to the conversion price reduction								$ 40,461	$ 168,835			$ 40,461		$ 30,938
Common stock issued per share						$ 1,000
Preferred stock, shares authorized							2,500	2,500				2,500		2,500
Preferred stock, par value per share							$ 0.001	$ 0.001				$ 0.001		$ 0.001
Preferred stock, dividend rate, percentage							10%
Preferred stock, liquidation preference per share							$ 1,000
Proceeds from private offering						$ 2,500,000
Debt conversion, original debt, amount						156,000
Preferred stock, shares issued								1,509				1,509		1,509
Preferred stock, shares outstanding								1,509				1,509		1,509
Issuance of common stock for cash												$ 642,018
Series B Preferred Stock [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Exchange ratio				$ 3
Issuance of common stock for cash				$ 642,018
Series B Preferred Stock [Member] | Fifteen Holders [Member]
Class of Stock [Line Items]
Accrued dividends					$ 53,061			$ 417,514				$ 417,514		$ 304,653
Shares converted					991
Common stock issued during conversion					163,134
Series B Preferred Stock [Member] | Warrant [Member] | Directors [Member]
Class of Stock [Line Items]
Debt conversion, original debt, amount						$ 23,000
Series B Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Conversion price								$ 5.42		$ 6.19		$ 5.42
Preferred stock, conversion price, decrease														$ 6.40
Series B Preferred Stock [Member] | Minimum [Member]
Class of Stock [Line Items]
Conversion price								$ 5.30		$ 5.42		$ 5.30
Preferred stock, conversion price, decrease														$ 6.19
Series E-1 Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized								8,500				8,500		8,500
Preferred stock, par value per share								$ 0.0001				$ 0.0001		$ 0.0001
Preferred stock, shares issued								0				0		0
Preferred stock, shares outstanding								0				0		0
Series E-1 Preferred Stock [Member] | Exchange Agreement [Member]
Class of Stock [Line Items]
Common stock issued per share			$ 12
Common stock issued during conversion			720,986
Fair value of shares converted			$ 8,650,000
Common shares vested												720,986
Series E-1 Preferred Stock [Member] | Employees and Directors [Member]
Class of Stock [Line Items]
Recognized stock based compensation												$ 0	$ 428,450
Series E-1 Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized															8,500
Common Stock [Member]
Class of Stock [Line Items]
Reverse stock split, description														40:1 reverse stock split

SUMMARY OF STOCK OPTION ACTIVIT

SUMMARY OF STOCK OPTION ACTIVITY (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Option outstanding, beginning balance	177,815
Weighted average exercise price outstanding, balance	$ 12.57
Weighted average remaining contractual term outstanding	8 years 21 days	8 years 9 months 18 days
Aggregate Intrinsic Value, Beginning balance
Options, granted
Weighted average exercise price, granted
Option outstanding, ending balance	177,815	177,815
Weighted average exercise price outstanding, ending balance	$ 12.57	$ 12.57
Aggregate intrinsic value, ending balance

STOCK OPTIONS (Details Narrativ

STOCK OPTIONS (Details Narrative) - USD ($)	1 Months Ended	9 Months Ended
	May 31, 2023	Sep. 30, 2023	Sep. 30, 2022	May 23, 2023	Dec. 31, 2016
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Issuance of common stock for cash, shares		1,191,792	269,775
Share based compensation expense		$ 395,083	$ 1,156,675
Options granted, amount
Unrecognized stock-based compensation		$ 279,895
2016 OmniBus Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares authorized under plan		105,898		550,000	4,000
Shares authorized under plan outstanding, percent		5%
2016 OmniBus Equity Incentive Plan [Member] | Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Issuance of common stock for cash, shares	269,102

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

6 Months Ended

9 Months Ended

12 Months Ended

Jul. 01, 2022

Apr. 30, 2022

May 31, 2023

Feb. 28, 2022

Jan. 31, 2022

Sep. 30, 2023

Mar. 31, 2023

Sep. 30, 2022

Jun. 30, 2022

Sep. 30, 2023

Sep. 30, 2022

Dec. 31, 2022

Loss Contingencies [Line Items]

Termination agreement description

The employment agreements as amended for the Company’s Executive Chairman and CEO each contain termination provisions whereby if they are terminated without cause or following a material change, as defined therein, they will receive salary through the date of termination plus an additional 24 months, bonus that would be earned during the full year when the termination became effective (or a lump sum of 50% of the full target bonus), all stock options shall vest and healthcare benefits will continue for 24 months. The Company’s General Counsel’s employment agreement, as amended, contains an 18-month severance payment in the instance of a termination without cause or following a material change, as defined therein. In June 2023, the Company’s General Counsel was provided the additional title of Executive Vice President – Corporate Development.

Employment agreements description

Pursuant to amendments dated November 14, 2022 to the three employment agreements of the Company’s Executive Chairman, CEO and EVP/General Counsel, as well as an amendment to the employment agreement for the Company’s VP Operations (the “2022 Amendments”), each of these four employees have agreed to accept reduced salaries until the Company is successful in raising additional funds. Specifically, when the Company raises at least $7.5 million in a single offering, each employee’s salary will be increased to the full contracted rate; and prior to that time, the reduced salaries will be gradually increased as the Company raises $2 million and then $5 million. During this time, the difference between the reduced salaries and the full contracted salaries will not accrue as liabilities for the Company.

Issuance of common stock for cash

$ 600,000

$ 314,246

Stock issued during period, value forfeitures

$ 5,000,000

Individual compensation expense

$ 30,000

Professional fees

444,463

$ 108,841

$ 1,352,962

$ 966,251

Employee agreement related description

These shares vest 50% upon a Nasdaq listing of the Company’s stock if completed within three years, and 50% in eight quarterly installments upon the sooner of the Nasdaq listing or 12 months from issuance. All shares will vest upon the sale, merger or other “exit” event of the Company. Pursuant to Board resolutions as of August 21, 2023, Dr. Link was awarded a transaction bonus in the instance any of the Company’s assets are sold or sublicensed or if the Company or its subsidiary is acquired, equal to 0.75% of the consideration received by the Company, to compensate him for services he previously performed for the Company as interim medical director.

Issuance of common stock for cash, shares

1,191,792

269,775

Research and development expenses

364,343

$ 245,853

$ 1,019,143

$ 704,902

Chairman and CEO [Member]

Loss Contingencies [Line Items]

Description of nature and effects

The employment agreements, as amended, for the Company’s Executive Chairman and CEO each contain a transaction bonus in the instance any of the Company’s assets are sold or sublicensed or if the Company or its subsidiary is acquired, equal to 1.75% of the consideration received by the Company. The employment agreement, as amended, for the Company’s EVP/General Counsel and for its VP Operations each contain a similar transaction bonus equal to 1.0% of consideration received by the Company, pursuant to a Board consent authorized and approved as of July 26, 2023. Pursuant to Board resolutions as of August 21, 2023, one of our directors was awarded a similar transaction bonus equal to 0.75% to compensate him for services he previously performed for the Company as interim medical director.

Adriann Sax [Member]

Loss Contingencies [Line Items]

Individual compensation expense

$ 30,000

Accrued compensation

$ 85,104

43,542

Audit Committee [Member]

Loss Contingencies [Line Items]

Professional fees

$ 7,500

7,500

Nominating and Governace Commmittee [Member]

Loss Contingencies [Line Items]

Professional fees

3,500

$ 10,000

Charles J. Link [Member]

Loss Contingencies [Line Items]

Individual compensation expense

30,000

Accrued compensation

100,333

$ 51,333

Charles J. Link [Member] | Restricted Stock [Member]

Loss Contingencies [Line Items]

Restricted stock issued as bonuses

10,455

Compensation Committee Chair [Member]

Loss Contingencies [Line Items]

Professional fees

$ 15,000

Settlement Agreement [Member]

Loss Contingencies [Line Items]

Accrued salaries

$ 758,748

758,748

Issuance of common stock for cash

606,998

Cash payments

151,750

Unpaid salaries

$ 79,166

Shares issued

168,611

Converted price per share

$ 3.55

$ 3.55

License Agreement [Member]

Loss Contingencies [Line Items]

Research and development expenses

$ 95,988

$ 0

Accounts payable and accrued expenses

$ 7,283

$ 7,283

License Agreement [Member] | IGL Pharma Inc [Member]

Loss Contingencies [Line Items]

Agreement term

20 years

License Agreement [Member] | QSAM Therapeutics Inc [Member]

Loss Contingencies [Line Items]

Other expenses

$ 64,136.50

Royalty percentage

4.50%

Sublicense percentage

5%

Consulting fee

$ 8,500

License Agreement [Member] | QSAM Therapeutics Inc [Member] | Upon Commercialization [Member]

Loss Contingencies [Line Items]

Other expenses

$ 2,000,000

Issuance of common stock for cash, shares

12,500

License Agreement [Member] | QSAM Therapeutics Inc [Member] | Maximum [Member]

Loss Contingencies [Line Items]

Other expenses

$ 410,000

Consulting Agreement [Member] | QSAM Therapeutics Inc [Member]

Loss Contingencies [Line Items]

Consulting fee

$ 8,500

Consulting Agreement [Member] | ISO Therapeutics Group Inc [Member]

Loss Contingencies [Line Items]

Consulting fee

$ 8,500

CORRECTION OF JUNE 30, 2023 F_2

CORRECTION OF JUNE 30, 2023 FINANCIAL STATEMENTS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2022
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Deemed dividends from Series A and B conversion price reduction	$ 40,461		$ 265,080	$ 305,541
Deemed dividend on warrant modification			$ 282,309	282,309	41,225
Net loss attributable to common stockholders	$ (1,249,575)	$ (1,278,975)		$ (4,631,527)	$ (4,480,353)
Earnings per share, basic	$ (0.36)	$ (0.75)	$ (1.27)	$ (1.60)	$ (2.66)
Earnings per share, diluted	$ (0.36)	$ (0.75)	$ (1.27)	$ (1.60)	$ (2.66)
Error Correction, Other [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net loss attributable to common stockholders			$ (3,381,540)
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net loss attributable to common stockholders			$ (2,834,151)
Earnings per share, basic			$ (1.07)
Earnings per share, diluted			$ (1.07)

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Oct. 31, 2023	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2023
Subsequent Event [Line Items]
Common stock issued		$ 600,000	$ 314,246
Series B Preferred Stock [Member]
Subsequent Event [Line Items]
Common stock issued				$ 642,018
Series B Preferred Stock [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Exchange ratio	$ 3
Common stock issued	$ 642,018